Cleidocranial dysplasia with decreased bone density and biochemical findings of hypophosphatasia

Éva Morava, Judit Kárteszi, János Weisenbach, Almuth Caliebe, Stefan Mundlos, Károly Méhes

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Cleidocranial dysplasia (CCD; MIM 119600) is an autosomal dominant skeletal dysplasia characterised by hypoplastic clavicles, patent fontanelles, short stature, tooth anomalies and other variable skeletal changes. Different mutations of the RUNX2/CBFA1 gene (MIM 600211) have been detected in patients with CCD. We investigated a mother and daughter with features of CCD presenting with reduced plasma alkaline phosphatase activity, increased urinary phosphoethanolamine excretion and decreased bone density. The latter findings were suggestive of hypophophatasia but mutation analysis showed no mutation in the tissue-nonspecific alkaline phosphatase gene (TNSALP; MIM 171760). However, a heterozygous mutation (Arg169Pro caused by nucleotide change 506G>C) was detected in the RUNX2 gene. Metabolic alterations gradually improved in both mother and daughter but bone-specific alkaline phosphatase remained low (less than 30% of normal) and mild phosphoethanolaminuria persisted. Recent studies in the Cbfa1 knock-out mouse showed decreased expression of alkaline phosphatase in differentiating bone. Conclusion: we suggest that the observed metabolic alterations are secondary to the RUNX2 gene mutation affecting early bone maturation and turnover. This is the first description of biochemical findings of hypophosphatasia in patients with cleidocranial dysplasia.

Original languageEnglish (US)
Pages (from-to)619-622
Number of pages4
JournalEuropean Journal of Pediatrics
Volume161
Issue number11
DOIs
StatePublished - Dec 31 2002

    Fingerprint

Keywords

  • Alkaline phosphatase
  • Cleidocranial dysplasia
  • Hypophosphatasia
  • Pyridoxal-5-phosphate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this